Targets › GRIK1
1 program from 1 company in 1 trial: 1 Phase 1; Psychiatry; next expected readout Oct 2027.
Ionotropic glutamate receptor that functions as a cation-permeable ligand-gated ion channel, gated by L-glutamate and the glutamatergic agonist kainic acid. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. (UniProt, P39086)
Open in Phaseline: the race on GRIK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Proniras | Tezampanel Glutamate receptor ionotropic AMPA antagonist; Glutamate receptor ionotropic kainate antagonist | GRIA4, GRIA3, GRIA2, GRIA1, GRIK1 | Phase 1 | Opioid Use Disorder | Oct 2027 |
Opioid Use Disorder (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.